RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Notice of Allowance for Key U.S. Heart Patent

10/7/2011 9:10:25 AM

ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for its application claiming methods for treating, preventing, inhibiting or reducing tissue deterioration due to congestive heart failure disease using Thymosin beta 4 (Tß4), its isoforms and fragments, and important analogs. The patent is projected to expire July 2027.

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• RegeneRx Biopharmaceuticals, Inc.

• Biotech/Pharma - Patent News